Alterity Therapeutics Launches to Asian Investors
Alterity Therapeutics Limited, (formerly Prana Biotechnology Limited) is meeting this week with sophisticated investors in both Singapore and Hong Kong in the first leg of a global investor roadshow.
Change of Company Name
We wish to announce the Company name change has been processed by the Australian Securities and Investment Commission and the Company has changed its name from “Prana Biotechnology Limited” to “Alterity Therapeutics Limited”.
Completion of investment by Life Biosciences LLC and capital raising update
Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) (ASX:PBT) (“Alterity” or “the Company”) is pleased to announce completion of the strategic investment by Life Biosciences LLC (Life) of an initial US$7.5m (A$10.526m at an exchange rate of A$1.00 to US$0.7125) in the Company (Subscription).
Results of General Meeting
The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a show of hands.
Prana EGM and Conference Call Facility
Prana Biotechnology today advises that a conference call facility will be available at the Extraordinary General Meeting (EGM) scheduled for Friday, April 5, 2019, at 11:00 AM AEDT.
Prana receives A$3.3 million R&D Tax Incentive
Prana has today announced that is has received a A$3.3 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.
Notice of General Meeting 2019
Prana receives Orphan Designation for PBT434 for treatment of MSA
Prana receives first orphan drug designation from the FDA for the treatment of Multiple System Atrophy